Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer,Thoracic Cancer

当前位置： X-MOL 学术 › Thorac. Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer
Thoracic Cancer ( IF 2.3 ) Pub Date : 2021-07-29 , DOI: 10.1111/1759-7714.14092
Jun Shiihara ₁ , Fumiyoshi Ohyanagi _{1,

2} , Hikari Amari ₁ , Minemichi Toda ₁ , Hiroki Tahara ₁ , Motoi Yuzawa ₁ , Yuki Maeda ₁ , Motoko Nomura ₁ , Yoshiko Mizushina _{1,

3} , Yoshiaki Nagai ₁ , Hiromitsu Ohta ₁ , Yasuhiro Yamaguchi ₁

Affiliation

Lung cancers with anaplastic lymphoma kinase (ALK) rearrangements are highly sensitive to treatment with ALK tyrosine kinase inhibitors (TKIs). Due to the very low rate of patients with squamous cell carcinoma enrolled in clinical trials, the efficacy of ALK inhibitors in patients with ALK-rearranged squamous cell carcinoma in the lung remains unclear. Herein, we present the case of a 70-year-old female patient with squamous cell lung cancer harboring the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion gene. The patient was treated with the ALK-TKI alectinib as first-line regimen and achieved a dramatic response without severe adverse events, demonstrating alectinib as a therapeutic option for patients with ALK-positive squamous cell carcinoma.

中文翻译：

ALK 重排鳞状细胞肺癌患者对艾乐替尼的显着反应

间变性淋巴瘤激酶 ( ALK ) 重排的肺癌对 ALK 酪氨酸激酶抑制剂 (TKI) 的治疗高度敏感。由于参加临床试验的鳞状细胞癌患者的比例非常低，ALK 抑制剂对肺 ALK 重排鳞状细胞癌患者的疗效仍不清楚。在此，我们介绍了一名患有鳞状细胞肺癌的 70 岁女性患者的病例，该患者携带棘皮动物微管相关蛋白样 4 ( EML4 )- ALK融合基因。该患者接受 ALK-TKI 艾乐替尼作为一线方案治疗，并取得了显着的反应，没有严重的不良事件，证明艾乐替尼是 ALK 阳性鳞状细胞癌患者的治疗选择。

更新日期：2021-09-02

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11